Overcoming Deadly Diseases
Phase 3 ACTION Study of ONC201 (dordaviprone) Now Enrolling
Improving and Extending Lives
Chimerix’s mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. Learn more about our approach to investing in novel drug candidates that meaningfully improve the probability of survival and the collaborative team driving the development of these promising new therapies.
Chimerix Announces the initiation of the ACTION study for patients with the H3K27M mutation.
- Chimerix Appoints Lisa Decker to Board of Directorson December 29, 2023
- Chimerix Promotes Michelle LaSpaluto to Chief Financial Officeron December 4, 2023